pregabalin efficacy in peripheral neuropathic pain results from the first 15 months of an ongoing...
TRANSCRIPT
![Page 1: Pregabalin Efficacy in Peripheral Neuropathic Pain Results from the first 15 months of an ongoing open-label study in patients with treatment-](https://reader035.vdocument.in/reader035/viewer/2022070401/56649f175503460f94c2eb36/html5/thumbnails/1.jpg)
![Page 2: Pregabalin Efficacy in Peripheral Neuropathic Pain Results from the first 15 months of an ongoing open-label study in patients with treatment-](https://reader035.vdocument.in/reader035/viewer/2022070401/56649f175503460f94c2eb36/html5/thumbnails/2.jpg)
![Page 3: Pregabalin Efficacy in Peripheral Neuropathic Pain Results from the first 15 months of an ongoing open-label study in patients with treatment-](https://reader035.vdocument.in/reader035/viewer/2022070401/56649f175503460f94c2eb36/html5/thumbnails/3.jpg)
![Page 4: Pregabalin Efficacy in Peripheral Neuropathic Pain Results from the first 15 months of an ongoing open-label study in patients with treatment-](https://reader035.vdocument.in/reader035/viewer/2022070401/56649f175503460f94c2eb36/html5/thumbnails/4.jpg)
![Page 5: Pregabalin Efficacy in Peripheral Neuropathic Pain Results from the first 15 months of an ongoing open-label study in patients with treatment-](https://reader035.vdocument.in/reader035/viewer/2022070401/56649f175503460f94c2eb36/html5/thumbnails/5.jpg)
![Page 6: Pregabalin Efficacy in Peripheral Neuropathic Pain Results from the first 15 months of an ongoing open-label study in patients with treatment-](https://reader035.vdocument.in/reader035/viewer/2022070401/56649f175503460f94c2eb36/html5/thumbnails/6.jpg)
![Page 7: Pregabalin Efficacy in Peripheral Neuropathic Pain Results from the first 15 months of an ongoing open-label study in patients with treatment-](https://reader035.vdocument.in/reader035/viewer/2022070401/56649f175503460f94c2eb36/html5/thumbnails/7.jpg)
![Page 8: Pregabalin Efficacy in Peripheral Neuropathic Pain Results from the first 15 months of an ongoing open-label study in patients with treatment-](https://reader035.vdocument.in/reader035/viewer/2022070401/56649f175503460f94c2eb36/html5/thumbnails/8.jpg)
Pregabalin Efficacy in Peripheral Neuropathic Pain
Results from the first 15 months of an ongoing open-label study in patients with treatment-refractory pain: Peripheral neuropathic pain analysis.
![Page 9: Pregabalin Efficacy in Peripheral Neuropathic Pain Results from the first 15 months of an ongoing open-label study in patients with treatment-](https://reader035.vdocument.in/reader035/viewer/2022070401/56649f175503460f94c2eb36/html5/thumbnails/9.jpg)
Refractory Pain Study – Peripheral Neuropathic Pain Analysis: Inclusion Criteria
• Patients with DPN or PHN who had previously taken part in placebo-controlled, double-blind pregabalin trials
• Refractory to:–Gabapentin ≥1800 mg/day AND–Tricyclic antidepressant ≥75 mg/day AND–≥1 3rd line agent (e.g. AED, narcotic, SSNRI, NSAID)
• Refractoriness defined as inadequate pain relief for 2 weeks and/or intolerable side-effects on each of the above–SF-MPQ pain VAS score ≥40 mm–Allowed to continue all pain medications–No inferential testing performed
Adapted from D'Urso De Cruz et al. Diabetes 2005; 54 (Suppl. 1): A139 (abstract).
![Page 10: Pregabalin Efficacy in Peripheral Neuropathic Pain Results from the first 15 months of an ongoing open-label study in patients with treatment-](https://reader035.vdocument.in/reader035/viewer/2022070401/56649f175503460f94c2eb36/html5/thumbnails/10.jpg)
Refractory Pain Study – Peripheral Neuropathic Pain Analysis: Design Overview
Treatment period 1
Drug holiday 1
Treatment period 2
Drug holiday 2
Treatment period 3
Drug holiday 3
Treatment period 4
Drug holiday 4
Treatment period 5
3 months 3-28 days 3 months 3-28 days 3 months 3-28 days 3 months 3-28 days 3 months
Relapse
Not at all = 1
A little worse =2
√ Moderately worse =3
√ Much worse =4
√ Very much worse =5
Relapse
“How much has your pain worsened since discontinuing study medication?”
Relapse RelapseRelapse
Treatment period = 3-month open-label treatment period with pregabalin 150-600 mg/dayDrug holiday = pregabalin drug holiday. Only 4 patients did not relapse during drug holidays.
Adapted from D'Urso De Cruz et al. Diabetes 2005; 54 (Suppl. 1): A139 (abstract).
![Page 11: Pregabalin Efficacy in Peripheral Neuropathic Pain Results from the first 15 months of an ongoing open-label study in patients with treatment-](https://reader035.vdocument.in/reader035/viewer/2022070401/56649f175503460f94c2eb36/html5/thumbnails/11.jpg)
Refractory Pain Study – Pain Reported on Pregabalin Treatment* and During Drug Holidays
DH = pregabalin drug holiday. Only 4 patients did not relapse during drug holidays.*15-month open-label pregabalin treatment analysis
Adapted from D'Urso De Cruz et al. Diabetes 2005; 54 (Suppl. 1): A139 (abstract).
![Page 12: Pregabalin Efficacy in Peripheral Neuropathic Pain Results from the first 15 months of an ongoing open-label study in patients with treatment-](https://reader035.vdocument.in/reader035/viewer/2022070401/56649f175503460f94c2eb36/html5/thumbnails/12.jpg)
Refractory Pain Study – Peripheral Neuropathic Pain Analysis: Distribution of Pain Severity at Baseline and 15 Months
No/Mild Pain: 0-39; Moderate Pain: 40-69; Severe Pain: ≥70 on SF-MPQ pain VAS15-month analysis (LOCF). Only 4 patients did NOT relapse during drug holidays.
Adapted from D'Urso De Cruz et al. Diabetes 2005; 54 (Suppl. 1): A139 (abstract).